<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03847493</url>
  </required_header>
  <id_info>
    <org_study_id>ASGARD</org_study_id>
    <nct_id>NCT03847493</nct_id>
  </id_info>
  <brief_title>Analysis of Sublingual Glycocalyx Damage at ICU Admission to Predict Risk of Death</brief_title>
  <acronym>ASGARD</acronym>
  <official_title>Analysis of Sublingual Glycocalyx Damage at ICU Admission to Predict Risk of Death - the ASGARD Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Muenster</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this observative, prospective study is to evaluate if and to what extent
      glycocalyx damage/microcirculation data at admission in the ICU as well as during ICU stay
      can be predictive of mortality and clinical course in patients presenting with the suspicion
      of sepsis/septic shock. Therefore, the enrollment of ca 100 ICU patients is planned.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Predictive value of glycocalyx thickness regarding clinical course.</measure>
    <time_frame>Hospital stay, an expected time of 4 weeks.</time_frame>
    <description>Glycocalyx thickness measured with the use of GlycoCheck System (Perfused Boundary Region - PBR, in µm). Clinical course will be estimated with the use of e.g. Sequential Organ Failure Assessment (SOFA) score (in points).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Predictive value of glycocalyx thickness regarding mortality.</measure>
    <time_frame>Hospital stay, an expected time of 4 weeks.</time_frame>
    <description>Glycocalyx thickness measured with the use of GlycoCheck System (Perfused Boundary Region - PBR, in µm).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of glycocalyx thickness with disease severity.</measure>
    <time_frame>Hospital stay, an expected time of 4 weeks.</time_frame>
    <description>Glycocalyx thickness will be measured with the use of GlycoCheck System (Perfused Boundary Region - PBR, in μm). Disease severity will be assessed with ICU scores (e.g. SOFA Score - pts)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Sepsis</condition>
  <condition>Septic Shock</condition>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>Patients with suspected sepsis</arm_group_label>
    <description>Patients admitted in the ICU with the clinical suspicion of infection/sepsis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-sepsis Patients (control group)</arm_group_label>
    <description>Patients admitted in the ICU with other conditions apart from infection/sepsis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Endothelial Glycocalyx</intervention_name>
    <description>Non-invasive assessment of endothelial glycocalyx dimensions.</description>
    <arm_group_label>Non-sepsis Patients (control group)</arm_group_label>
    <arm_group_label>Patients with suspected sepsis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Non-consecutive patients admitted in the ICU of University Hospital Münster, Germany.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ICU patients admitted to the ICU with the clinican suspicion of sepsis/septic shock.

        Exclusion Criteria:

          -  Underage persons, pregnant women, patients with inflammation or trauma of sublingual
             mucosa.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philipp Kümpers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Muenster</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philipp Kümpers, MD</last_name>
    <phone>0049 (0)251 83 47516</phone>
    <email>philipp.kuempers@ukmuenster.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandros Rovas, MD</last_name>
    <phone>0049 (0)251 83 47516</phone>
    <email>alexandros.rovas@ukmuenster.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitiy Hospital Muenster</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philipp Kümpers, MD</last_name>
      <phone>+49 (0)251 / 83 - 47516</phone>
      <email>philipp.kuempers@ukmuenster.de</email>
    </contact>
    <contact_backup>
      <last_name>Alexandros Rovas, MD</last_name>
      <phone>+49 (0)251 / 83 - 47516</phone>
      <email>alexandros.rovas@ukmuenster.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 14, 2019</study_first_submitted>
  <study_first_submitted_qc>February 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2019</study_first_posted>
  <last_update_submitted>May 2, 2019</last_update_submitted>
  <last_update_submitted_qc>May 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>perfused boundary region</keyword>
  <keyword>PBR</keyword>
  <keyword>Sepsis</keyword>
  <keyword>endothelial glycocalyx</keyword>
  <keyword>ICU</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

